ACTUACIÓN FRENTE A COVID19 EN RECEPTORES DE TRASPLANTE DE PROGENITORES HEMATOPOYÉTICOS Y PACIENTES ONCOHEMATOLÓGICOS (COVID-19) (GETH-COV-2020-01)

Study identification

• EU PAS number:
  EUPAS34365
• Study ID:
  36967
• Official title and acronym:
  ACTUACIÓN FRENTE A COVID19 EN RECEPTORES DE TRASPLANTE DE PROGENITORES HEMATOPOYÉTICOS Y PACIENTES ONCOHEMATOLÓGICOS (COVID-19) (GETH-COV-2020-01)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  Retrospective study in which TPH/ONCOHEMATOLOGICAL patients will be included, that is to say, immunosuppressed patients such as the recipients of allogeneic or autologous transplants of haematopoietic progenitors (alo or auto-TPH), of CAR-T therapy and oncohaematological patients in chemotherapeutic and/or immunosuppressive treatment from centres participating in the GETH. The collection will be done by CRD on-line or on paper.It will be done in two phases:1st phase at the time of diagnosis, only the minimum data that will allow later identification of the patient will be collected (initial registration sheet). Send by email.2nd phase once the episode is over (Complementary registration sheet). Send by email.Translated with www.DeepL.com/Translator (free version)
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 70 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned:20/03/2020

Actual:20/03/2020

Study start date

Planned:23/03/2020

Actual:23/03/2020

Data analysis start date

Planned:30/06/2020

Actual:15/06/2020

Date of final study report

Planned:30/07/2020

Actual:16/07/2020

Sources of funding

Other

More details on funding

GETH

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable